journal article·2016-12

Gold nanoparticle-capped mesoporous silica-based H2O2-responsive controlled release system for Alzheimer’s disease treatment

Licong Yang, Tiantian Yin, Yanan Liu, Jing Sun, Yanhui Zhou, Jie Liu

Acta Biomaterialia· Volume 46
Publisher page

Abstract

Metal ions promote Alzheimer's disease (AD) pathogenesis by accelerating amyloid-β (Aβ) aggregation and inducing formation of neurotoxic reactive oxygen species (ROS) such as hydrogen peroxide (H2O2). Although metal chelators can block these effects, their therapeutic potential is marred by their inability to cross the blood-brain barrier (BBB) and by their non-specific interactions with metal ions necessary for normal cellular processes, which could result in adverse side effects. To overcome these limitations, we created a novel gold nanoparticle-capped mesoporous silica (MSN-AuNPs) based H2O2-responsive controlled release system for targeted delivery of the metal chelator CQ. In this system, CQ is released only upon exposure to conditions in which H2O2 levels are high, such as those in Aβ plaques. The conjugation of AuNPs on the surface of MSN did not affect their ability to cross the BBB. The AuNPs also help in decrease the Aβ self-assembly, due to this, MSN-CQ-AuNPs were more efficient than MSN-CQ in inhibiting Cu2+-induced Aβ40 aggregation. Furthermore, MSN-CQ-AuNPs reduced the cell membrane disruption, microtubular defects and ROS-mediated apoptosis induced by Aβ40-Cu2+ complexes. The high BBB permeability, efficient anti-Aβ aggregation, and good biocompatibility of MSN-CQ-AuNPs, together with the specific conditions necessary for its release of CQ, demonstrate its potential for future biomedical applications. Statement of significance Due to the low ability to cross the blood-brain barrier (BBB) and non-specific interactions with metal ions necessary for normal cellular processes of metal chelator or Aβ inhibitors, we created a novel gold nanoparticle-capped mesoporous silica (MSN-AuNPs)-based H2O2-responsive controlled release system for targeted delivery of the metal chelator CQ and AuNPs (Aβ inhibitor). In this system, CQ and AuNPs are released only upon exposure to conditions in which H2O2 levels are high, such as those in Aβ plaques. The AuNPs on the surface of MSN also help in decrease the Aβ self-assembly, due to this, MSN-CQ-AuNPs were more efficient than MSN-CQ in inhibiting Cu2+-induced Aβ40 aggregation. Furthermore, MSN-CQ-AuNPs reduced the cell membrane disruption, microtubular defects and ROS-mediated apoptosis induced by Aβ40-Cu2+ complexes. Our data suggest that this controlled release system may have widespread application in the field of medicine for Alzheimer's disease.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Alzheimer's disease research and treatments · Nanocluster Synthesis and Applications · Cholinesterase and Neurodegenerative Diseases

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (49)

Show source-provided references
1. Alzheimer’s disease: from pathology to therapeutic approaches10.1002/anie.200802808 ↗
2. Medicinal inorganic chemistry approaches to passivation and removal of aberrant metal ions in disease10.1021/cr9000176 ↗
3. Pathways towards and away from Alzheimer’s disease10.1038/nature02621 ↗
4. Mechanisms of disease Alzheimer’s disease10.1056/NEJMra0909142 ↗
5. Apoptosis is induced by beta-amyloid in cultured central nervous system neurons10.1073/pnas.90.17.7951 ↗
6. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches10.1038/nn1335 ↗
7. Intraneuronal Abeta accumulation and origin of plaques in Alzheimer’s disease10.1016/j.neurobiolaging.2005.05.022 ↗
8. Amyloid-β and tau–a toxic pas de deux in Alzheimer’s disease10.1038/nrn2967 ↗
9. Zinc ions promote Alzheimer A beta aggregation via population shift of polymorphic states10.1073/pnas.0913114107 ↗
10. Inhibitory action of macrocyclic platiniferous chelators on metal-induced A beta aggregation10.1039/c2sc01100j ↗
11. The metallobiology of Alzheimer’s disease10.1016/S0166-2236(03)00067-5 ↗
12. Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence10.1021/bi0272151 ↗
13. The role of oxidative stress in the toxicity induced by amyloid beta-peptide in Alzheimer’s disease10.1016/S0301-0082(00)00015-0 ↗
14. Ceria/POMs hybrid nanoparticles as a mimicking metallopeptidase for treatment of neurotoxicity of amyloid-β peptide10.1016/j.biomaterials.2016.05.005 ↗
15. Chelation therapy for neurodegenerative diseases10.1002/med.20148 ↗
16. Bifunctional compounds for controlling metal-mediated aggregation of the A beta(42) peptide10.1021/ja210588m ↗
17. Nuclear-targeted drug delivery of TAT peptide-conjugated monodisperse mesoporous silica nanoparticles10.1021/ja211035w ↗
18. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers10.1016/j.addr.2008.03.012 ↗
19. Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals10.1002/smll.201000538 ↗
20. Mesoporous silica nanoparticles as a delivery system of gadolinium for effective human stem cell tracking10.1002/smll.200701316 ↗
21. Size effect on cell uptake in well-suspended, uniform mesoporous silica nanoparticles10.1002/smll.200900005 ↗
22. Delivery of small interfering RNA by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers10.1021/nn204102q ↗
23. Use of size and a copolymer design feature to improve the biodistribution and the enhanced permeability and retention effect of doxorubicin-loaded mesoporous silica nanoparticles in a murine xenograft tumor model10.1021/nn200809t ↗
24. In vitro and in vivo studies on the transport of PEGylated silica nanoparticles across the blood-brain barrier10.1021/am405219u ↗
25. Mesoporous silica nanoparticle-based double drug delivery system for glucose-responsive controlled release of insulin and cyclic AMP10.1021/ja901831u ↗
26. Biotin-avidin as a protease-responsive cap system for controlled guest release from colloidal mesoporous silica10.1002/anie.200805818 ↗
27. Mesoporous silica nanoparticle-based H2O2 responsive controlled-release system used for Alzheimer’s disease treatment10.1002/adhm.201200067 ↗
28. Negatively charged gold nanoparticles inhibit Alzheimer’s amyloid-beta fibrillization, induce fibril dissociation, and mitigate neurotoxicity10.1002/smll.201201068 ↗
29. Highly specific enrichment of glycopeptides using boronic acid-functionalized mesoporous silica10.1021/ac801912t ↗
30. Synthesis and extraction of beta-D-glucose-stabilized Au nanoparticles processed into low-defect, wide-area thin films and ordered arrays using CO2-expanded liquids10.1021/la060450q ↗
31. A detailed examination of boronic acid-diol complexation10.1016/S0040-4020(02)00489-1 ↗
32. 4-mercaptophenylboronic acid SAMs on gold: Comparison with SAMs derived from thiophenol, 4-mercaptophenol, and 4-mereaptobenzoic acid10.1021/la7007733 ↗
33. A biocompatible oxidation-triggered carrier polymer with potential in therapeutics10.1021/ja110468v ↗
34. The blood-brain barrier in health and chronic neurodegenerative disorders10.1016/j.neuron.2008.01.003 ↗
35. Targeted delivery of nano-therapeutics for major disorders of the central nervous system10.1007/s11095-013-1122-4 ↗
36. Increased delivery of TAT across an endothelial monolayer following ischemic injury10.1016/j.neulet.2010.09.029 ↗
37. Evaluation of the immortalised mouse brain capillary endothelial cell line, b.End3, as an in vitro blood-brain barrier model for drug uptake and transport studies10.1016/S0006-8993(03)03443-7 ↗
38. Nanotechnologies for Alzheimer’s disease: diagnosis, therapy, and safety issues10.1016/j.nano.2011.03.008 ↗
39. A specific amyloid-beta protein assembly in the brain impairs memory10.1038/nature04533 ↗
40. Se/Ru nanoparticles as inhibitors of metal-induced A beta aggregation in Alzheimer’s disease10.1039/C3TB21586E ↗
41. Single molecule characterization of the interactions between amyloid-beta peptides and the membranes of hippocampal cells10.1021/ja3103567 ↗
42. Examination of potential mechanisms of amyloid-induced defects in neuronal transport10.1016/j.nbd.2009.05.016 ↗
43. Short multiwall carbon nanotubes promote neuronal differentiation of PC12 cells via up-regulation of the neurotrophin signaling pathway10.1002/smll.201201388 ↗
44. Disruption of axonal transport by loss of huntingtin or expression of pathogenic PolyQ proteins in Drosophila10.1016/S0896-6273(03)00594-4 ↗
45. Axonopathy and transport deficits early in the pathogenesis of Alzheimer’s disease10.1126/science.1105681 ↗
46. Tacrine-6-ferulic acid, a novel multifunctional dimer, inhibits amyloid-beta-mediated Alzheimer’s disease-associated pathogenesis in vitro and in vivo10.1371/journal.pone.0031921 ↗
47. A matter of life and cell death10.1126/science.281.5381.1317 ↗
48. Inhibition of metal-induced amyloid aggregation using light-responsive magnetic nanoparticle prochelator conjugates10.1039/C1SC00631B ↗
49. Role of reactive oxygen species (ROS) in apoptosis induction10.1023/A:1009616228304 ↗